CAS910463-68-2 Semaglutide Gip GLP-1 Peptide Tirzepatide White Lyophilized Powder

Semaglutide is a highly efficient glucagon-like peptide-1 (GLP-1) receptor agonist, belonging to the category of polypeptide biopharmaceuticals. It is produced through genetic recombination technology using Saccharomyces cerevisiae cells, and its molecular structure has been specially modified to possess excellent metabolic stability and biological activity. As a new-generation GLP-1 drug, it not only demonstrates outstanding blood glucose control effects in the treatment of type 2 diabetes but is also approved for chronic weight management, with the additional benefit of reducing the risk of adverse cardiovascular events. It is currently a key focus in the pharmaceutical field.

The Semaglutide raw materials we supply are prepared using a combined process of original fermentation and total chemical synthesis, with a purity of over 99.5%. They strictly adhere to cGMP production standards and are available in various specifications including oral and injectable grades, catering to the diverse requirements of downstream formulation development. Our products are exported to Southeast Asia, the Americas, Europe, and other regions, accounting for 70% of our sales, and have gained wide recognition from global customers.

Core mechanism of action

Semaglutide exerts multiple pharmacological effects through precise activation of the GLP-1 receptor:
- Blood glucose regulation: It promotes secretion from pancreatic β cells when blood glucose levels rise, while simultaneously inhibiting the release of glucagon from pancreatic α cells, achieving glucose-dependent blood glucose regulation and reducing the risk of hypoglycemia.
Weight management: Slows down the gastric emptying rate, prolongs the feeling of fullness, and acts on the central nervous system to suppress appetite, significantly reducing overall body weight and abdominal fat accumulation. It is particularly suitable for obese or overweight individuals.
Cardiovascular protection: By improving vascular endothelial function and reducing inflammatory responses, it lowers the risk of cardiovascular death, non-fatal myocardial infarction and stroke in patients with type 2 diabetes.
Stability advantage: The introduction of 2-aminoisobutyric acid (Aib) and the modification with an 18-carbon fatty acid chain in the molecular structure make it more resistant to degradation by DPP-4 enzymes, with a high serum albumin binding rate and a half-life of up to 7 days, supporting once-weekly dosing.